SLC5A2 and heart failure: An area of intense current research, HFpEF represents about half of all patients with heart failure and is a syndrome for which therapeutic options are limited to the recent discovery of the efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors6.